Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Shih

Showing results (581-590 of 615) with videos related to

Pageof 62
Sort By:
Cancer Discovery|March 14, 2019
Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in CancerDong Chen, Siyuan Xia, Mei Wang, et al.
The Journal of Biological Chemistry|November 14, 2012
An ultra-specific avian antibody to phosphorylated tau protein reveals a unique mechanism for phosphoepitope recognitionHeather H Shih, Chao Tu, Wei Cao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2020
Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic ResponseFatima Karzai, Stephanie M Walker, Scott Wilkinson, et al.
American Journal of Respiratory and Critical Care Medicine|February 12, 2025
Broad Immunomodulatory Effects of the Dipeptidyl-peptidase-1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW TrialEmma D Johnson, Merete B Long, Lidia Perea, et al.
Nature Communications|February 14, 2024
The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancerChandra Sekhar Amara, Karthik Reddy Kami Reddy, Yang Yuntao, et al.
Cancer Discovery|May 31, 2024
CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify KDM3B as a Genotype-specific Vulnerability in IDH2- and TET2-mutant CellsMichael R Waarts, Shoron Mowla, Meaghan Boileau, et al.
The Journal of Experimental Medicine|November 13, 2013
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivoOmar Abdel-Wahab, Jie Gao, Mazhar Adli, et al.
Cancer Discovery|May 12, 2019
Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AMLCihangir Duy, Matt Teater, Francine E Garrett-Bakelman, et al.
Nature|June 29, 2018
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutationsAndrew M Intlekofer, Alan H Shih, Bo Wang, et al.
The Lancet Regional Health. Western Pacific|August 7, 2023
The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumoursAya El Helali, Tai-Chung Lam, Elaine Yee-Ling Ko, et al.
Pageof 62

Showing results (581-590 of 615) with videos related to

Sort By:
Pageof 62
Cancer Discovery|March 14, 2019
Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in CancerDong Chen, Siyuan Xia, Mei Wang, et al.
The Journal of Biological Chemistry|November 14, 2012
An ultra-specific avian antibody to phosphorylated tau protein reveals a unique mechanism for phosphoepitope recognitionHeather H Shih, Chao Tu, Wei Cao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2020
Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic ResponseFatima Karzai, Stephanie M Walker, Scott Wilkinson, et al.
American Journal of Respiratory and Critical Care Medicine|February 12, 2025
Broad Immunomodulatory Effects of the Dipeptidyl-peptidase-1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW TrialEmma D Johnson, Merete B Long, Lidia Perea, et al.
Nature Communications|February 14, 2024
The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancerChandra Sekhar Amara, Karthik Reddy Kami Reddy, Yang Yuntao, et al.
Cancer Discovery|May 31, 2024
CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify KDM3B as a Genotype-specific Vulnerability in IDH2- and TET2-mutant CellsMichael R Waarts, Shoron Mowla, Meaghan Boileau, et al.
The Journal of Experimental Medicine|November 13, 2013
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivoOmar Abdel-Wahab, Jie Gao, Mazhar Adli, et al.
Cancer Discovery|May 12, 2019
Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AMLCihangir Duy, Matt Teater, Francine E Garrett-Bakelman, et al.
Nature|June 29, 2018
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutationsAndrew M Intlekofer, Alan H Shih, Bo Wang, et al.
The Lancet Regional Health. Western Pacific|August 7, 2023
The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumoursAya El Helali, Tai-Chung Lam, Elaine Yee-Ling Ko, et al.
Pageof 62